Supplementary Material for: Exploring the Policies Applied to Pharmaceutical Care Practice for Type 2 Diabetes over the Last Decade in European Community Pharmacies

In the last decade (2010–2020), more than half of European countries have improved their health policies within the primary care for type 2 diabetes mellitus. Community pharmacies have been and could continue to be essential actors in this evolution of fighting the disease by providing a set of pharmacotherapeutic follow-up services for the person with diabetes. These services, designated by the Pharmaceutical Group of the European Union as “diabetes management” and “glucose measurement”, have aimed to optimize adherence to therapy and improve health outcomes. However, to follow the European guidelines of Good Pharmacy Practice, providing these services implies having a normative framework or a legal basis. Thus, this study sought to analyze the normative and regulatory framework on which community pharmacies in 28 European countries were based on providing this health care over the last decade.

在2010至2020年的十年间，超过半数欧洲国家已针对2型糖尿病（type 2 diabetes mellitus）的基层医疗健康政策完成优化升级。社区药房此前已是、未来亦可继续成为该疾病防控进程中的核心参与主体，通过为糖尿病患者提供一系列药物治疗随访服务助力疾病防控。欧盟制药集团（Pharmaceutical Group of the European Union）将此类服务界定为“糖尿病管理”与“血糖检测”，其核心目标为提升患者治疗依从性并改善健康结局。然而，若要遵循《优良药房工作规范》（Good Pharmacy Practice）的欧洲指南，提供上述服务必须具备规范性框架或法律依据。因此，本研究旨在分析近十年间，28个欧洲国家的社区药房开展此类医疗服务所依托的规范性与监管框架。